- AstraZeneca Plc’s AZN top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung cancer.
- The European Commission has approved the lung cancer drug as an add-on (adjuvant) treatment for adults diagnosed early enough for the tumor to be surgically removed and have a mutation of the EGFR gene.
- The approval was based on positive results from a late-stage trial, ADAURA, which showed Tagrisso cut the risk of the tumor growing back in patients or death by 80%.
- Tagrisso brought in sales of $1.15 billion in the first quarter.
- Price Action: AZN shares are down 0.21% at $56.77 in the premarket session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
